Michelle G Craske1, Michael Fanselow2, Michael Treanor2, Alexander Bystritksy3. 1. Staglin Center for Brain and Behavioral Health, Department of Psychology, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California. Electronic address: mcraske@mednet.ucla.edu. 2. Staglin Center for Brain and Behavioral Health, Department of Psychology, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California. 3. Department of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: In rodents, context specificity of Pavlovian extinction is attenuated by manipulations that impair hippocampal function, including systemic administration of scopolamine, a muscarinic-cholinergic receptor antagonist. Context renewal translates into return of fear following exposure therapy to feared situations. We evaluated the effectiveness of scopolamine for attenuating context renewal of phobic fear in humans. METHODS: A total of 60 participants (35 female, 22 male, 1 transgender, 2 undeclared) with social anxiety disorder and fear of public speaking were randomized to placebo, 0.5 mg scopolamine, or 0.6 mg scopolamine. They completed seven exposure sessions in an exposure context and subsequently tested in the exposure context (extinction retest) versus a different context (context renewal test), which were counterbalanced. Testing 1 month later occurred in the exposure context (long-term extinction retest). Fear measures included skin conductance and self-reported distress during speeches. Hippocampus-dependent cognitive tasks were completed as well. RESULTS:Scopolamine augmented extinction across exposure sessions on skin conductance response and skin conductance level. Lower skin conductance response at context renewal in scopolamine groups relative to the placebo group was constrained to simple effects and complicated by unexpected outcomes within placebo and on self-reported fear. Scopolamine led to lower skin conductance response at long-term extinction retest. Scopolamine impaired performance on a cognitive task of hippocampal function. CONCLUSIONS: Noninvasive and well-tolerated scopolamine impaired hippocampal processes and augmented extinction during exposure. Drug-free effects persisted 1 month later. Findings at context renewal were limited and suggestive only. Further investigation is warranted with varying scopolamine dosages.
RCT Entities:
BACKGROUND: In rodents, context specificity of Pavlovian extinction is attenuated by manipulations that impair hippocampal function, including systemic administration of scopolamine, a muscarinic-cholinergic receptor antagonist. Context renewal translates into return of fear following exposure therapy to feared situations. We evaluated the effectiveness of scopolamine for attenuating context renewal of phobic fear in humans. METHODS: A total of 60 participants (35 female, 22 male, 1 transgender, 2 undeclared) with social anxiety disorder and fear of public speaking were randomized to placebo, 0.5 mg scopolamine, or 0.6 mg scopolamine. They completed seven exposure sessions in an exposure context and subsequently tested in the exposure context (extinction retest) versus a different context (context renewal test), which were counterbalanced. Testing 1 month later occurred in the exposure context (long-term extinction retest). Fear measures included skin conductance and self-reported distress during speeches. Hippocampus-dependent cognitive tasks were completed as well. RESULTS:Scopolamine augmented extinction across exposure sessions on skin conductance response and skin conductance level. Lower skin conductance response at context renewal in scopolamine groups relative to the placebo group was constrained to simple effects and complicated by unexpected outcomes within placebo and on self-reported fear. Scopolamine led to lower skin conductance response at long-term extinction retest. Scopolamine impaired performance on a cognitive task of hippocampal function. CONCLUSIONS: Noninvasive and well-tolerated scopolamine impaired hippocampal processes and augmented extinction during exposure. Drug-free effects persisted 1 month later. Findings at context renewal were limited and suggestive only. Further investigation is warranted with varying scopolamine dosages.
Authors: Kevin L Brown; John A Kennard; Daniel J Sherer; David M Comalli; Diana S Woodruff-Pak Journal: Behav Brain Res Date: 2011-07-30 Impact factor: 3.332
Authors: Moriel Zelikowsky; Timothy A Hast; Rebecca Z Bennett; Michael Merjanian; Nathaniel A Nocera; Ravikumar Ponnusamy; Michael S Fanselow Journal: Biol Psychiatry Date: 2012-09-12 Impact factor: 13.382
Authors: David C Knight; Dominic T Cheng; Christine N Smith; Elliot A Stein; Fred J Helmstetter Journal: J Neurosci Date: 2004-01-07 Impact factor: 6.167
Authors: Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske Journal: Psychoneuroendocrinology Date: 2020-03-20 Impact factor: 4.905
Authors: Murray B Stein; Joel Gelernter; Daniel F Levey; Zhongshan Cheng; Frank R Wendt; Kelly Harrington; Gita A Pathak; Kelly Cho; Rachel Quaden; Krishnan Radhakrishnan; Matthew J Girgenti; Yuk-Lam Anne Ho; Daniel Posner; Mihaela Aslan; Ronald S Duman; Hongyu Zhao; Renato Polimanti; John Concato Journal: Nat Genet Date: 2021-01-28 Impact factor: 38.330